Metformin Hydrochloride; Sitagliptin Phosphate Patent Expiration
Metformin Hydrochloride; Sitagliptin Phosphate is used for managing type 2 diabetes mellitus with the combination of sitagliptin and metformin HCl extended release, either alone or with insulin. It was first introduced by Merck Sharp And Dohme Llc A Sub Of Merck And Co Inc
Metformin Hydrochloride; Sitagliptin Phosphate Patents
Given below is the list of patents protecting Metformin Hydrochloride; Sitagliptin Phosphate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Janumet | US6303661 | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr 24, 2017
(Expired) | Msd Sub Merck |
| Janumet | US6699871 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul 26, 2022
(Expired) | Msd Sub Merck |
| Janumet |
US6699871 (Pediatric) | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan 26, 2023
(Expired) | Msd Sub Merck |
| Janumet | US6890898 | Method of regulating glucose metabolism, and reagents related thereto |
Feb 02, 2019
(Expired) | Msd Sub Merck |
| Janumet | US7078381 | Method of regulating glucose metabolism, and reagents related thereto |
Feb 02, 2019
(Expired) | Msd Sub Merck |
| Janumet | US7125873 | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul 26, 2022
(Expired) | Msd Sub Merck |
| Janumet |
US7125873 (Pediatric) | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan 26, 2023
(Expired) | Msd Sub Merck |
| Janumet | US7326708 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | Nov 24, 2026 | Msd Sub Merck |
| Janumet |
US7326708 (Pediatric) | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | May 24, 2027 | Msd Sub Merck |
| Janumet | US7459428 | Method of regulating glucose metabolism, and reagents related thereto |
Feb 02, 2019
(Expired) | Msd Sub Merck |
| Janumet | US8414921 | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin | Jul 21, 2028 | Msd Sub Merck |
| Janumet |
US8414921 (Pediatric) | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin | Jan 21, 2029 | Msd Sub Merck |
| Janumet Xr | US6303661 | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr 24, 2017
(Expired) | Msd Sub Merck |
| Janumet Xr | US6340475 | Extending the duration of drug release within the stomach during the fed mode |
Sep 19, 2016
(Expired) | Msd Sub Merck |
| Janumet Xr | US6635280 | Extending the duration of drug release within the stomach during the fed mode |
Sep 19, 2016
(Expired) | Msd Sub Merck |
| Janumet Xr | US6699871 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul 26, 2022
(Expired) | Msd Sub Merck |
| Janumet Xr |
US6699871 (Pediatric) | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan 26, 2023
(Expired) | Msd Sub Merck |
| Janumet Xr | US6890898 | Method of regulating glucose metabolism, and reagents related thereto |
Feb 02, 2019
(Expired) | Msd Sub Merck |
| Janumet Xr | US7078381 | Method of regulating glucose metabolism, and reagents related thereto |
Feb 02, 2019
(Expired) | Msd Sub Merck |
| Janumet Xr | US7125873 | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul 26, 2022
(Expired) | Msd Sub Merck |
| Janumet Xr |
US7125873 (Pediatric) | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan 26, 2023
(Expired) | Msd Sub Merck |
| Janumet Xr | US7326708 | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | Nov 24, 2026 | Msd Sub Merck |
| Janumet Xr |
US7326708 (Pediatric) | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | May 24, 2027 | Msd Sub Merck |
| Janumet Xr | US7459428 | Method of regulating glucose metabolism, and reagents related thereto |
Feb 02, 2019
(Expired) | Msd Sub Merck |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳